Prati-Donaduzzi is committing R$1 billion, about 40% of its 2025 revenue, to a new 5-billion-dose solid-dose plant in Paraná as it pushes toward international markets.

MANUFACTURING · GENERIC DRUG MANUFACTURING · NOVEMBER 1, 2026 · BRAZIL
On September 22, 2026, Prati-Donaduzzi, a pharmaceutical manufacturer based in Toledo, Paraná, that Exame described in 2023, citing IQVIA data, as Brazil’s largest generics maker by volume, announced a R$1 billion capital cycle that includes a new solid-dose factory capable of producing 5 billion doses per year, according to Exame.
The new unit, called Sólidos 5, will be built at Biopark, a technology park in Toledo created by the company’s founders, Carmen and Luiz Donaduzzi, after they stepped back from day-to-day management. The facility will have 10 production lines and is projected to raise Prati-Donaduzzi’s total output by 30%, per the company’s announcement. The expansion is also expected to generate 500 direct jobs.
R$1 billion
Prati-Donaduzzi announced a R$1 billion investment cycle that includes the Sólidos 5 plant, equal to approximately 40% of the company’s 2025 revenue of R$2.5 billion, according to Exame.
The scale of the commitment reflects a specific physical constraint. Prati-Donaduzzi’s existing industrial perimeter in Toledo is fully occupied, according to Exame, which is why the new plant will go to the Biopark. The company already operates a distribution center within the park; Sólidos 5 would add manufacturing to that footprint.
From domestic scale to export ambition
Eder Maffissoni, chief executive of Prati-Donaduzzi, framed the investment explicitly in international terms. “The new plant is part of Prati-Donaduzzi’s preparation for its next growth cycles. We are expanding our production capacity with an eye not only on demand in the Brazilian market but also on our internationalization goals,” he said in a statement carried by Exame (translated from Portuguese by HealthSignals). In a separate quote, Maffissoni added: “We want to build today the structure the company needs to expand its presence in other markets and compete increasingly on a global scale.”
The international ambition has a documented starting point. Prati-Donaduzzi has exported to the United States for more than a decade via private-label arrangements, in which it manufactures products sold under third-party brands. In 2024, the company moved beyond that model, launching Sensilatte — a product for people with lactose intolerance — in the US market under its own brand. Maffissoni described the nutraceutical category, which combines characteristics of foods and supplements, as a test for broader international expansion, according to Exame. The company’s stated long-term objective at the time was to reach 50 countries within 15 years.
That trajectory also includes a semaglutide generic. Exame reported in April 2024 that Prati-Donaduzzi had begun developing its own equivalent of Novo Nordisk’s semaglutide (Ozempic), targeting the patent expiry in Brazil then projected for 2026. The company sourced active pharmaceutical ingredients from Asian suppliers and the injection device from European ones, and was in the formulation and analysis phase at the time of that report. Maffissoni compared the anticipated market opening to the period after the patent on Viagra (sildenafil) expired.
Revenue base and the R$4 billion target
Prati-Donaduzzi reported revenue of R$2.5 billion in 2025, according to Exame. The R$1 billion investment cycle therefore represents approximately 40% of that annual figure. In 2023, revenue was about R$2.3 billion, per Exame, which reported in 2023 and 2024 a target of reaching R$4 billion in revenue by 2027. Prati-Donaduzzi traditionally invests 5% of the prior year’s revenue in research and development, according to Exame’s April 2024 reporting.
The competitive backdrop for that target has grown more complex. Valor Econômico reported in September 2025 that at least four Brazilian pharmaceutical companies — EMS, Aché, Hypera, and União Química — were expected to submit bids for the assets of Medley, the generics business owned by the French group Sanofi. Prati-Donaduzzi was not named among the bidders in that report. In March 2026, EMS agreed to buy Medley from Sanofi, according to Brazil Journal, which said EMS, already the country’s generics leader, would reach a 31% market share with the deal. The deal requires approval from the Conselho Administrativo de Defesa Econômica (CADE), Brazil’s antitrust authority, which in September 2026 decided to deepen its review, according to InvestNews.
The friction in the international expansion thesis is regulatory, not industrial. Building 5 billion doses of annual capacity is a different undertaking from obtaining the product registrations and manufacturing-site approvals required to sell those doses in the US or European markets. Prati-Donaduzzi’s strategy, as described by Exame, involves developing new products from the outset to meet the regulatory requirements of target export markets. The Sensilatte launch in the US represents a single nutraceutical product, not a pharmaceutical registration, and Exame’s most recent reporting on the semaglutide program, from April 2024, placed it in the formulation and analysis phase.
What to Watch
- Whether Prati-Donaduzzi files a semaglutide generic registration with Agência Nacional de Vigilância Sanitária (ANVISA), Brazil’s health regulatory agency; Exame last reported the program in the formulation and analysis phase in April 2024
- CADE’s decision on EMS’s acquisition of Medley, whose statutory review deadline is January 22, 2027, according to InvestNews
- Progress on Prati-Donaduzzi’s pharmaceutical product registrations in the US and European markets, which would convert the Sólidos 5 capacity into export revenue rather than domestic overflow
The Biopark location carries a structural implication that the investment figure alone does not capture. By building inside a campus that already houses companies, universities, and research centers — and that was created by the company’s founders — Prati-Donaduzzi is positioning its next manufacturing cycle adjacent to the talent and research infrastructure it will need if the portfolio continues to move beyond commodity generics.
Prati-Donaduzzi Expansion Metrics · Sólidos 5 Plant
| Figure | Source | |
|---|---|---|
| Investment cycle announced | R$1 billion | Exame |
| New plant annual capacity | 5 billion doses | Exame |
| Production increase from new plant | 30% | Exame |
| Direct jobs to be created | 500 | Exame |
| Production lines in Sólidos 5 | 10 | Exame |
| Investment as share of 2025 revenue | ~40% | Exame |
Why this is relevant
Patients
Prati-Donaduzzi’s Sólidos 5 plant, with 5 billion doses of annual capacity and 10 production lines, would add domestic capacity for solid-dose medicines; Exame gave no construction or start-up dates, so any effect on supply is not yet scheduled.
Industry
The R$1 billion commitment, equivalent to roughly 40% of Prati-Donaduzzi’s 2025 revenue of R$2.5 billion, comes as EMS, which Brazil Journal describes as the generics leader, seeks to absorb Medley, pending CADE approval.
Payers
Additional generic manufacturing capacity is relevant to public tenders and private formularies, though the timeline between construction completion and stocked supply depends on regulatory registration cycles.
Regulators
Agência Nacional de Vigilância Sanitária (ANVISA), Brazil’s health regulatory agency, may receive registration filings from Prati-Donaduzzi for the semaglutide program Exame reported in 2024 and for products the company develops to meet US and European requirements.
Sources: Exame: Gigante farmacêutica do Paraná investe R$ 1 bilhão em nova fábrica para 5 bilhões de doses · Exame: Farmacêutica Prati, do Paraná, entra na briga e começa a desenvolver o seu ‘Ozempic’ · Exame: Farmacêutica Prati, do Paraná, investe R$ 1,2 bilhão e quer fazer aquisições · Valor Econômico: Ativos da farmacêutica Medley atraem quatro gigantes nacionais · Brazil Journal: EMS compra a Medley e consolida liderança em genéricos · InvestNews: Cade decide aprofundar análise da compra da Medley pela EMS
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.







